News

News

Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson’s Disease

You are here Targeting Alpha-Synuclein in the Gut May Slow Down Parkinson’s Disease 13 November 2019 Scientists are testing the hypothesis that by targeting the gut with a compound that can inhibit the aggregation of alpha-synuclein, they may be able to slow the progression of Parkinson’s disease Amsterdam, NL – Aggregates of the protein alpha-synuclein arising in the gut may ...

11/18/2019

Cibus Achieves Critical Milestones for Three Non-GMO Traits to Increase Canola Yield

Cibus, a pioneer of precision gene editing for agriculture, has reached significant milestones in developing three new traits for canola, which can increase crop yields for farmers and reduce harmful environmental impacts.

11/6/2019

Harris Healthcare Acquires Connecture, Inc.

N. Harris Computer Corporation’s (“Harris”) healthcare group announced today that it has completed the acquisition of Connecture, Inc. (“Connecture”).…

10/7/2019

ADC Therapeutics Files Registration Statement for Proposed Initial Public Offering

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company pioneering the development of highly potent and targeted antibody drug conjugates for patients suffering from hematological malignancies and solid tumors, announced today that it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public ...

9/6/2019

X-Vax Technology Raises $56 Million in Upsized Series A Financing to Advance Lead Herpes Vaccine Program

A new approach to beating herpes by inducing antibodies that mediate the killing of infected cells -Participants include Johnson & Johnson Innovation – JJDC, Inc. (JJDC); Adjuvant Capital, an impact investment fund supported by the Bill & Melinda Gates Foundation as an anchor investor; Serum Institute of India; Alexandria Venture Investments; Founders Fund. X-Vax Technology NEWS PROVIDED BY X-Vax Technology, ...

7/23/2019

FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference

FibroGen, Inc. (NASDAQ: FGEN), today announced that the company will present interim data on their open-label, single-arm…

6/28/2019

FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…

6/10/2019

FibroGen Reports First Quarter 2019 Financial Results

Positive topline results from pooled safety analyses of roxadustat Phase 3 global program Completed one year of treatment in Phase 2 trial evaluating pamrevlumab in…

5/9/2019

FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program

MACE/MACE+ endpoints evaluated across CKD patients not on dialysis and on dialysis Superiority in time to first MACE+ versus epoetin alfa in incident dialysis patients…

5/9/2019

FibroGen Receives Orphan Drug Designation from the U.S. FDA For Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy

FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…

4/15/2019

FibroGen Reports Fourth Quarter and Full Year 2018 Financial Results

FibroGen, Inc. (NASDAQ: FGEN), a leading biopharmaceutical company discovering and developing a pipeline of first-in-class therapeutics, today…

2/27/2019

Connecture Announces The Sale Of Its Commercial U65 Business Unit to Benefitfocus

Connecture, Inc. announces the sales of its Commercial U65 business unit to Benefitfocus With the sale of the U65…

2/26/2019

Crossmatch Fingerprint Reader Provides Biometric Security for ThinkPad T490 Healthcare Edition

Crossmatch®, part of HID Global, today announced its fingerprint reading technology is enabling secure identity management on the newly revealed Lenovo ThinkPad T490 Healthcare Edition.…

2/12/2019